Cabaletta Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cabaletta Bio, Inc. on June 1, 2023, regarding events occurring at the Company's 2023 Annual Meeting of Stockholders held on the same date. The Company is a Delaware corporation with its principal executive offices in Philadelphia, PA.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance results.
Material Changes and Corporate Actions
- Equity Plan Amendment: Stockholders approved Amendment No. 1 to the 2019 Stock Option and Incentive Plan, increasing the number of shares reserved for issuance by 3,000,000 shares.
- Director Election: Scott Brun, M.D., was elected as a Class I director to serve a three-year term expiring at the 2026 annual meeting.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results
| Proposal | For | Against/Withheld | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Scott Brun, M.D. | 23,574,643 | 1,168,107 (Withheld) | N/A | 2,540,395 |
| Amendment to 2019 Plan | 21,684,293 | 3,045,532 | 12,925 | 2,540,395 |
| Ratification of Ernst & Young LLP | 27,268,632 | 5,343 | 9,170 | 0 |
Outlook, Risks, and Management Commentary
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation by reference to the Proxy Statement filed on April 21, 2023.
Key Facts for Investor Verification
- Verify the total number of shares outstanding as of the record date (April 3, 2023) was 29,480,230.
- Confirm the impact of the 3,000,000 share increase on the 2019 Plan on future dilution.
- Review the definitive Proxy Statement (Schedule 14A) for detailed terms of the equity plan amendment and director qualifications.
- Note that the Company is classified as an emerging growth company.